View More View Less
  • 1 Debreceni Egyetem, Orvos- és Egészségtudományi Centrum Belgyógyászati Intézet, II. Belgyógyászati Klinika, Hematológiai Tanszék Debrecen Nagyerdei krt. 98. 4032
Restricted access

A tumorlízis-szindróma súlyos metabolikus eltérésekkel jellemezhető onkológiai krízisállapot. Leggyakrabban lymphoproliferatív kórképekben szenvedő betegekben fordul elő kemoterápiát követően. Ritkán spontán módon is kialakulhat. Patofiziológiai szempontból a daganatsejtek sejtszétesését követően jelentős mennyiségben felszabaduló kálium, foszfát és húgysav a legfontosabb. A húgysav és kálcium-foszfát kristályoknak a vesetubulusokban való lerakódása heveny veseelégtelenséghez vezethet. A kezelés hidrálásból, az acidosis és a hyperkaliaemia korrigálásából, az urát-nephropathia megelőzésére irányuló allopurinol vagy rekombináns urát oxidáz (rasburicase) alkalmazásából (és szükség esetén hemodialízisből) tevődik össze. A szerzők beszámolnak egy akut myeloid leukémiás betegük esetéről is, akinél a kemoterápiát követően súlyos tumorlízis-szindrómát észleltek.

  • Davidson, M. B., Thakkar, S., Hix, J. K. és mtsai: Pathophysiology, clinical consequences, and treatment of tumor lysis syndrome. Am. J. Med., 2004, 116 , 546–554.

    Hix J. K. , 'Pathophysiology, clinical consequences, and treatment of tumor lysis syndrome ' (2004 ) 116 Am. J. Med. : 546 -554.

    • Search Google Scholar
  • Cheson, B. D., Frame, J. N., Vena, D. és mtsai: Tumor lysis syndrome: an uncommon complication of fludarabine therapy of chronic lymphocytic leukemia. J. Clin. Oncol., 1998, 16 , 2313–2320.

    Vena D. , 'Tumor lysis syndrome: an uncommon complication of fludarabine therapy of chronic lymphocytic leukemia ' (1998 ) 16 J. Clin. Oncol. : 2313 -2320.

    • Search Google Scholar
  • Cohen, L. F., Balow, J. E., Magrath, I. T. és mtsai: Acute tumor lysis syndrome. A review of 37 patients with Burkitt’s lymphoma. Am. J. Med., 1980, 68 , 486–491.

    Magrath I. T. , 'Acute tumor lysis syndrome. A review of 37 patients with Burkitt’s lymphoma ' (1980 ) 68 Am. J. Med. : 486 -491.

    • Search Google Scholar
  • Coiffier, B., Mounier, N., Bologna, S. és mtsai: Efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive Non-Hodgkin’s lymphoma: results of the GRAAL1 (Groupe d’Etude des Lymphomes de l’Adulte Trial on Rasburicase Activity in Adult Lymphoma) study. J. Clin. Oncol., 2003, 21 , 4402–4406.

    Bologna S. , 'Efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive Non-Hodgkin’s lymphoma: results of the GRAAL1 (Groupe d’Etude des Lymphomes de l’Adulte Trial on Rasburicase Activity in Adult Lymphoma) study ' (2003 ) 21 J. Clin. Oncol. : 4402 -4406.

    • Search Google Scholar
  • Karagiannis, A., Tsorlalis, I., Kakafika, A. és mtsai: Acute renal failure due to tumor lysis syndrome in a patient with non-Hodgkin’s lymphoma. Ann. Hematol., 2005, 84 , 343–346.

    Kakafika A. , 'Acute renal failure due to tumor lysis syndrome in a patient with non-Hodgkin’s lymphoma ' (2005 ) 84 Ann. Hematol. : 343 -346.

    • Search Google Scholar
  • Harris, K. P. G., Hattersley, J. M., Feehally, J. és mtsa: Acute renal failure associated with haematological malignancies: A review of 10 years experience. Eur. J. Haematol., 1991, 47 , 119–122.

    Feehally J. , 'Acute renal failure associated with haematological malignancies: A review of 10 years experience ' (1991 ) 47 Eur. J. Haematol. : 119 -122.

    • Search Google Scholar
  • Leonov, Y., Golik, A., Kaufman, S. és mtsa: Acute tumour lysis syndrome with extreme metabolic abnormalities. Clin. Lab. Haemat., 1987, 9 , 85–89.

    Kaufman S. , 'Acute tumour lysis syndrome with extreme metabolic abnormalities ' (1987 ) 9 Clin. Lab. Haemat. : 85 -89.

    • Search Google Scholar
  • Arrambide, K., Toto, R. D.: Tumor lysis syndrome. Semin. Nephrol., 1993, 13 , 273–280.

    Toto R. D. , 'Tumor lysis syndrome ' (1993 ) 13 Semin. Nephrol. : 273 -280.

  • Gröbner, W., Zöllner, N.: Gicht. Z. Rheumatol., 2004, 63 , 2–9.

    Zöllner N. , 'Gicht ' (2004 ) 63 Z. Rheumatol. : 2 -9.

  • Tausche, A. K., Unger, S., Richter, K. és mtsai: Hyperurikämie und Gicht. Diagnostik und Therapie. Der Internist. Springer, 2006.

  • Goldman, S. C.: Rasburicase: potential role in managing tumor lysis in patients with hematological malignancies. Expert. Rev. Anticancer. Ther., 2003, 3(4) , 429–433.

    Goldman S. C. , 'Rasburicase: potential role in managing tumor lysis in patients with hematological malignancies ' (2003 ) 3 Expert. Rev. Anticancer. Ther. : 429 -433.

    • Search Google Scholar
  • Hediger, M. A., Johnson, R. J., Miyazaki, H. és mtsa: Molecular physiology of urate transport. Physiology, 2005, 20 , 125–133.

    Miyazaki H. , 'Molecular physiology of urate transport ' (2005 ) 20 Physiology : 125 -133.

  • Hummel, M., Buchheidt, D., Reiter, S. és mtsai: Recurrent chemotherapy-induced tumor lysis syndrome (TLS) with renal failure in a patient with chronic lymphocytic leukemia– successful treatment and prevention of TLS with low-dose rasburicase. Eur. J. Haematol., 2005, 75 , 518–521.

    Reiter S. , 'Recurrent chemotherapy-induced tumor lysis syndrome (TLS) with renal failure in a patient with chronic lymphocytic leukemia– successful treatment and prevention of TLS with low-dose rasburicase ' (2005 ) 75 Eur. J. Haematol. : 518 -521.

    • Search Google Scholar
  • Kiss Cs.: Sürgősségi ellátást igénylő gyermekhematológiai állapotok. Focus. Med., 1999, 1 , 29–37.

    Kiss Cs. , 'Sürgősségi ellátást igénylő gyermekhematológiai állapotok ' (1999 ) 1 Focus. Med. : 29 -37.

    • Search Google Scholar
  • Pession, A., Barbieri, E., Santoro, N. és mtsai: Efficacy and safety of recombinant urate oxidase (rasburicase) for treatment and prophylaxis of hyperuricemia in children undergoing chemotherapy. Haematologica, 2005, 90 , 141–142.

    Santoro N. , 'Efficacy and safety of recombinant urate oxidase (rasburicase) for treatment and prophylaxis of hyperuricemia in children undergoing chemotherapy ' (2005 ) 90 Haematologica : 141 -142.

    • Search Google Scholar
  • Liu, C. Y., Sims-McCallum, R. P., Schiffer, C. A.: A single dose of rasburicase is sufficient for the treatment of hyperuricemia in patients receiving chemotherapy. Leuk. Res., 2005, 29 , 463–465.

    Schiffer C. A. , 'A single dose of rasburicase is sufficient for the treatment of hyperuricemia in patients receiving chemotherapy ' (2005 ) 29 Leuk. Res. : 463 -465.

    • Search Google Scholar
  • Pui, C.-H., Jeha, S., Irwin, D. és mtsa: Recombinant urate oxidase (rasburicase) in the prevention and treatment of malignancy-associated hyperuricemia in pediatric and adult patients: results of a compassionate-use trial. Leukemia, 2001, 15 , 1505–1509.

    Irwin D. , 'Recombinant urate oxidase (rasburicase) in the prevention and treatment of malignancy-associated hyperuricemia in pediatric and adult patients: results of a compassionate-use trial ' (2001 ) 15 Leukemia : 1505 -1509.

    • Search Google Scholar
  • Berg van den, H., Reintsema, A. M.: Renal tubular damage in rasburicase: risks of alkalinisation. DOI: 10.1093/annonc/mdh029.

  • Pui, C.-H., Mahmoud, H. H., Wiley, J. M. és mtsai: Recombinant urate oxidase for the prophylaxis or treatment of hyperuricaemia in patients with leukaemia or lymphoma. J. Clin. Oncol., 2001, 19 , 697–704.

    Wiley J. M. , 'Recombinant urate oxidase for the prophylaxis or treatment of hyperuricaemia in patients with leukaemia or lymphoma ' (2001 ) 19 J. Clin. Oncol. : 697 -704.

    • Search Google Scholar
  • Goldman, S. C., Holcenberg, J. S., Finklestein, J. Z. és mtsai: A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis. Blood, 2001, 97 , 2998–3003.

    Finklestein J. Z. , 'A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis ' (2001 ) 97 Blood : 2998 -3003.

    • Search Google Scholar
  • Lim, E. M., Bennett, P., Beilby, J.: Sample preparation in patients receiving uric acid oxidase (rasburicase) therapy. Clin. Chem., 2003, 49 , 1417–1419.

    Beilby J. , 'Sample preparation in patients receiving uric acid oxidase (rasburicase) therapy ' (2003 ) 49 Clin. Chem. : 1417 -1419.

    • Search Google Scholar
  • Ueng, S.: Rasburicase (Elitek): a novel agent for tumor lysis syndrome. B. U. M. C. Proceedings, 2005, 18 , 275–279.

    Ueng S. , 'Rasburicase (Elitek): a novel agent for tumor lysis syndrome ' (2005 ) 18 B. U. M. C. Proceedings : 275 -279.

    • Search Google Scholar
  • Holdsworth, M. T., Nguyen, P.: Role of i.v. allopurinol and rasburicase in tumor lysis syndrome. Am. J. Health-System. Pharmacy, 2003, 60 , 2213–2222.

    Nguyen P. , 'Role of i.v. allopurinol and rasburicase in tumor lysis syndrome ' (2003 ) 60 Am. J. Health-System. Pharmacy : 2213 -2222.

    • Search Google Scholar
All Time Past Year Past 30 Days
Abstract Views 143 143 16
Full Text Views 31 5 0
PDF Downloads 15 7 0